Pinna, Annalisa published the artcileNovel investigational adenosine A2A receptor antagonists for Parkinson’s disease, Application of 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, the publication is Expert Opinion on Investigational Drugs (2009), 18(11), 1619-1631, database is CAplus and MEDLINE.
A review. The development of non-dopaminergic therapies for Parkinson’s disease (PD) has attracted much interest in recent years. Among new classes of drugs, adenosine A2A antagonists have emerged as the best candidates. BIIB014, preladenant and ST-1535 are new adenosine A2A antagonists currently in Phase I and II clin. trials for evaluation of their efficacy in patients with PD. All these compounds have been proven safe and well tolerated. Moreover, results from Phase II trials also demonstrate that BIIB014 and preladenant are effective in reducing the waking time spent in OFF state in patients at the late stage of PD treated with L-DOPA. BIIB014 is also efficacious as monotherapy in patients at the early stage of PD. Finally, ST-1535, at this time, displays a very promising potential in exptl. models of PD and a safe profile in clin. studies. This review summarizes pharmacol. data available on these three A2A antagonists, their effects in animal models of PD and their profiles in clin. trials.
Expert Opinion on Investigational Drugs published new progress about 377727-87-2. 377727-87-2 belongs to triazoles, auxiliary class GPCR/G Protein,Adenosine Receptor, name is 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, and the molecular formula is C25H29N9O3, Application of 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine.
Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics